­
­
­
­

Inventi Impact: Cardiovascular Nursing

Articles

  • Inventi:hcvn/42721/21
    Electrocardiographic Safety of Daily Hydroxychloroquine 400 mg Plus Azithromycin 250 mg as an Ambulatory Treatment for COVID-19 Patients in Cameroon
    01-Jul-2021 Research 2021 : July - September
    Liliane Mfeukeu-Kuate, William Djomo Ngatchou, Mazou Ngou Temgoua, Charles Kouanfack, Daniel Lemoungoum, Joel Noutakdie Tochie, Armel Zemsi, Lauriane Fomete, Skinner Lekelem, Sylvain Zemsi, Joelle Sobngwi, Thierry Ntandzi, Christian Ngongang Ouankou, Yves Wasnyo, Antoinette Tsama Assiga, Jan René Nkeck, Ahmadou Musa Jingi, Magellan Guewo, Eric Walter Pefura Yone, Charlotte Moussi Omgba, Paul Owono Etoundi, Jean Cyr Yombi, Samuel Kingue, Alain Menanga, Jacqueline Ze Minkande, Pierre Ongolo Zogo, Jean Claude Mbanya, Pierre Joseph Fouda, Eugène Sobngwi

    Objective: To determine the early electrocardiographic changes in a cohort of ambulatory cameroonian COVID-19 patients treated with hydroxychloroquine and Azithromycin. Design: Prospective study. Setting: Treatment centres of the city of Yaounde, Cameroon, from May 7th to 24th 2020. Participants: We enrolled 51 consecutive confirmed COVID-19 on RT-PCR who having mild forms of COVID-19 and treated by hydroxychloroquine 200 mg twice daily during seven #days plus Azithromycin 500 mg the first day and 250 mg the remaining 4 days as per national standard..............

    How to Cite this Article
    Attribution/ CC Compliant Citation: Mfeukeu-Kuate, Liliane, et al. "Electrocardiographic safety of daily hydroxychloroquine 400mg plus azithromycin 250mg as an ambulatory treatment for COVID-19 patients in Cameroon." (2020). https://doi.org/10.4236/wjcd.2021.112012 https://creativecommons.org/licenses/by/4.0/ Some formatting elements, header, footer, logos, dates and pagination were modified while adapting this article.
    Download Full Text